A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.
The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.
Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.
Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.
Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.
Early data of the Orca-T cellular therapy showed enough positive results from patients on the therapy to move on to a phase 3 study in this patient population.
Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.
Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.
A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.
The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.
Treatment with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel is safe and effective for patients with relapsed/refractory multiple myeloma.
Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.
Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.
Yann-Alexandre Vano, MD, discusses the main findings from the phase 2 BIONIKK trial that were presented at the 2023 Genitourinary Cancers Symposium.
Novel treatments are needed to replace transplant and prevent graft-vs-host disease in order to improve patient outcomes.
A 90-day complete response rate of 92% was observed with bispecific CAR T-cell therapy for patients with relapsed/refractory mantle cell lymphoma.
Tumor mutation burden was linked with improved survival while some alterations were linked with inferior outcomes from treatment with enfortumab vedotin for urothelial carcinoma.
At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.
Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.
According to findings presented at the 2023 Transplantation & Cellular Therapy Meetings, experts did not identify clear correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib in patients with graft-vs-host-disease.
Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.
In 8 patients with various hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors, Orca-T led to a 100% survival rate.
In a single-institution phase 1 trial, patients with large B-cell lymphoma had high overall response rates with CD22-directed CAR T-cell therapy.
Findings from the phase 2 HCRN GU 16-257 trial may help advance a more personalized approach to the management of muscle-invasive bladder cancer.
The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.
Final safety and efficacy read outs of the EQUATE trial show durable clinical responses and a favorable safety profile for acute graft-vs-host disease.
Long-term outcomes did not differ among de novo late acute graft-vs-host disease and classic acute graft-vs-host disease, showing they should be treated the same way.
Guru P. Sonpavde, MD, discusses The Cancer Genome Atlas and key takeaways for community oncologists.